New findings highlighted in recent research on EEG and migraine add to the growing body of evidence supporting advances in interventional psychiatry and neuromodulation. As clinicians increasingly seek personalized treatment strategies, identifying biological markers that predict therapeutic response has become a major focus across neurological and psychiatric care.
Migraine affects millions of people worldwide and remains one of the leading causes of disability. Although medications can reduce symptom burden for many patients, treatment responses vary widely. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising noninvasive intervention, but researchers continue searching for ways to determine which patients are most likely to benefit before treatment begins.
Current Challenges In Migraine Neuromodulation
TMS has demonstrated potential in reducing migraine symptoms, yet clinicians still face uncertainty when selecting optimal treatment candidates. Traditional clinical assessments provide valuable information, but they do not always explain why some individuals experience substantial symptom relief while others achieve only modest improvements.
This variability has fueled interest in objective biomarkers that could guide treatment planning. Electroencephalography (EEG), which measures electrical activity across the brain, offers a practical and relatively accessible method for examining neural function in real time.
Why EEG Biomarkers For Migraine Treatment Matter
In a 2026 study published in the Journal of Integrative Neuroscience, investigators evaluated resting-state EEG activity in patients with migraine before they underwent a course of rTMS targeting the left dorsolateral prefrontal cortex.
The researchers compared EEG recordings from migraine patients with recordings from healthy individuals matched for age and sex. Their goal was not only to identify neural abnormalities associated with migraine but also to determine whether these abnormalities could predict response to neuromodulation therapy.
This approach reflects a broader shift toward precision medicine, where treatment decisions are increasingly informed by measurable biological characteristics rather than symptoms alone.
Distinct Brain Activity Patterns Emerged
The study revealed several notable differences between migraine patients and healthy controls.
One key finding involved peak alpha frequency (PAF), a measure of alpha-wave activity commonly associated with information processing and cognitive function. Patients with migraine exhibited a slower PAF compared with healthy participants.
Researchers also identified increased alpha-band connectivity between parieto-occipital regions and between frontal and occipital brain areas. This pattern of hyperconnectivity suggests that communication between certain neural networks may be altered in individuals experiencing migraine.
Importantly, these differences were not merely descriptive observations. Some of the identified connectivity patterns appeared to carry meaningful predictive information regarding treatment outcomes.
Predicting Response To TMS
Perhaps the most clinically relevant result involved parieto-occipital connectivity.
The investigators found that connectivity measures within this network demonstrated predictive value for the analgesic effects of rTMS. In practical terms, patients displaying specific connectivity characteristics before treatment were more likely to experience meaningful pain reduction following TMS therapy.
If replicated in larger studies, this finding could help clinicians identify patients most likely to benefit from neuromodulation while reducing trial-and-error approaches to treatment selection.
Such predictive capabilities could improve efficiency, lower treatment burden, and support more individualized care plans.
Understanding The Potential Mechanism
Migraine is increasingly viewed as a disorder involving abnormal network dynamics rather than isolated dysfunction in a single brain region.
The observed alpha-band abnormalities may reflect disruptions in how sensory information is processed and integrated across distributed neural systems. TMS may influence these networks by modulating cortical excitability and altering communication patterns between interconnected regions.
By measuring these oscillatory signatures before treatment, EEG may provide a window into the functional state of migraine-related networks and their capacity to respond to stimulation.
What Makes This Research Different
Many migraine studies focus primarily on symptom outcomes. This investigation went a step further by examining baseline brain activity as a predictor of therapeutic success.
The combination of EEG-derived biomarkers and neuromodulation outcomes represents an important step toward biomarker-guided treatment. Rather than asking whether TMS works for migraine in general, researchers are beginning to ask which patients are most likely to benefit and why.
That distinction may ultimately prove critical for advancing personalized neuromodulation.
Looking Ahead For Precision Neuromodulation
While larger validation studies remain necessary, the findings suggest that EEG biomarkers for migraine treatment could play a meaningful role in future TMS protocols.
As biomarker-driven approaches continue to evolve, clinicians may eventually use EEG assessments to tailor stimulation parameters, refine patient selection, and optimize outcomes. For the field of interventional psychiatry and neuromodulation, studies like this move the conversation beyond efficacy alone and toward precision treatment strategies grounded in measurable brain activity.
The long-term goal is straightforward: delivering the right treatment to the right patient at the right time.
Citations
Wang Y, Han Y, Huang M, et al. Identifying neural oscillation and phase synchronization abnormalities in migraine and their predictive values in transcranial magnetic stimulation. Journal of Integrative Neuroscience. 2026. PMID: 42220293. https://pubmed.ncbi.nlm.nih.gov/42220293/
Wang Y, Han Y, Huang M, et al. Full Open Access Article. Journal of Integrative Neuroscience. 2026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13223903/
Explore more at https://www.interventionalpsychiatry.org/